Evaluation of two kinds of chemotherapy on advanced non-small-cell cancer

Objective:To evaluate the efficacy and adverse reactions of gemcitabine plus cisplatin ( GP ) and docetaxel plus cisplatin ( DP ) in the treatment of advanced non-small-cell lung cancer ( NSCLC ). Methods:Sixty-eight patients with NSCLC selected by certain criteria were divided into 2 groups (group A and B),each group had 34 cases,the inclusive criteria included:ECOG ≤ 2 points,survival time more than three months,WBC counts4.0×109/ L ,normal liver and renal function,no symptoms and signs of active infection,III or Ⅳ stage of pathology. Patients in group A were treated with gemcitabine plus cisplatin (GP) [gemcitabinei(G) 1 000 mg/m2,intravenous infusion,D1,8; cisplatin (P) 80 mg/m2,intravenous infusion,D1-5] and patients in group B were treated with docetaxel plus cisplatin (DP) [docetaxel (D) 75mg/m2,intravenous infusion,D1,cisplatin (P) 80mg/m2,intravenous infusion,D1-5]. The efficacy and adverse reactions were observed and studied. Results:The objective overall response rates of group A and B were 41.2% and 47.1% respectively,the difference between group A and B was not significant(P0.05). The Ⅲ~Ⅳ degree adverse reactions were less than total adverse reactions in the two groups,the incidence of thrombocytopenia in group A was significantly higher than that in group B (P0.05),the incidence of hair loss in group A was significantly lower than that in group B (P0.05); 3 / 4 degree of adverse reactions including local reactions,hair loss,constipation,and peripheral neuritis in group B were significantly higher than that in group A (P0.05),the other 3 / 4 degree of adverse reactions were no significant difference between the group A and B(P0.05). 1-year survival rate in group A and B was 41.2% and 44.1% respectively,the median time to disease progression in group A and B was 5.8 months and 6.1 months respectively. Conclusion:New platinum-based combining chemotherapy,such as GP and DP,has higher efficacy and more safety; it could be a new and better chemotherapy of advanced NSCLC.